Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Polydatin, a natural precursor of resveratrol found in Polygonum cuspidatum and other plants, has been studied in preclinical settings for its potential cardiovascular benefits, including effects relevant to arteriosclerosis. Several animal and cell-based studies suggest that polydatin may exert antioxidant, anti-inflammatory, and lipid-lowering effects, all of which are important in the pathophysiology of arteriosclerosis. For example, research has shown that polydatin can reduce oxidative stress and inhibit the expression of adhesion molecules and inflammatory cytokines in vascular endothelial cells, potentially slowing the progression of arterial plaque formation (Zhao et al., 2018, Mol Med Rep). Additionally, polydatin has demonstrated the ability to improve lipid profiles and inhibit vascular smooth muscle cell proliferation in animal models (Wang et al., 2015, J Pharmacol Sci).

However, while these findings are promising, most evidence remains limited to laboratory and animal research. There are few, if any, high-quality clinical trials directly investigating polydatin's efficacy in human arteriosclerosis. As such, while there is a scientific rationale and preclinical evidence supporting its use, the overall strength of evidence is currently limited. Further clinical studies are needed to confirm the effects and determine appropriate dosing and safety in humans.

More about Polydatin
More about Arteriosclerosis

Other ingredients used for Arteriosclerosis

Other health conditions supported by Polydatin

Products containing Polydatin